Bioneutra Global Stock Today
| BGACF Stock | USD 0.07 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 65
|
BioNeutra Global is trading at 0.067 as of the 23rd of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.067. BioNeutra Global has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for BioNeutra Global are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
BioNeutra Global Corporation, together with its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods, and beverages with a focus on oligosaccharides. The company has 46.45 M outstanding shares. More on BioNeutra Global
BioNeutra Pink Sheet Highlights
| Business Concentration | Packaged Foods, Consumer Defensive (View all Sectors) |
BioNeutra Global [BGACF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Nano-Cap' category with a current market capitalization of 863.36 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNeutra Global's market, we take the total number of its shares issued and multiply it by BioNeutra Global's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioNeutra Global classifies itself under Consumer Defensive sector and is part of Packaged Foods industry. The entity has 46.45 M outstanding shares.
BioNeutra Global has accumulated about 1.93 M in cash with 271.05 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check BioNeutra Global Probability Of Bankruptcy
Ownership AllocationBioNeutra Global holds a total of 46.45 Million outstanding shares. BioNeutra Global retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioNeutra Ownership Details
BioNeutra Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioNeutra Global without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
BioNeutra Global Corporate Management
| Ross Montagano | Chief Officer | Profile | |
| Sheri OBrien | VP Marketing | Profile | |
| Monica Barclay | Co Sec | Profile | |
| Vinti Goel | VP Affairs | Profile | |
| Jianhua Zhu | CEO, Founder | Profile | |
| Yiyuan Jiang | Chief Officer | Profile |
Other Information on Investing in BioNeutra Pink Sheet
BioNeutra Global financial ratios help investors to determine whether BioNeutra Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioNeutra with respect to the benefits of owning BioNeutra Global security.